Oncotab, Inc.

Charlotte, NC · Biotech · Private

Bispecific antibodies targeting tumor-associated MUC1 and CD3 for pancreatic and breast cancer immunotherapy

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · candiaginc.com

Sector: Biotech
Headquarters: Charlotte, NC
Total capital: $2M

Federal grants: $1.7M; 6 awards · 2016–2025; Rank in peer group#323 of 502
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $300K; 1 award · Health and Human S; Rank in Biotech#263 of 4373
Granted patents: 2; 1 pending · first 2023; Rank in peer group#41 of 502

Capital timeline

Latest events

May 2025Federal grantHealth and Human S · Phase I · Optimized targeted radiotherapy of pancreatic cancer$400K
Sep 2021Federal grantHealth and Human S · Phase I · The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma$261K
Sep 2021Federal grantHealth and Human S · Phase I · The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma$261K
Sep 2021Federal grantHealth and Human S · Phase I · An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer.$400K
Sep 2016Federal contractHealth and Human S · Igf::ot::igf Development Of Targeted Radionuclide Therapy Using Tumor Specific Antibody For Triple Negative Breast Cancer$300K
Jun 2016Federal grantHealth and Human S · Phase I · Novel immunotherapy strategy for treatment of pancreatic cancer$182K
May 2016Federal grantHealth and Human S · Phase I · Novel immunotherapy strategy for treatment of pancreatic cancer$182K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#41 · top 8%
Linked publications#3 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 3

Apr 21, 2026GrantedTumor Specific Antibody Conjugates And Uses ThereforUSPTOUS 12,605,469
Jan 17, 2023GrantedTumor Specific Antibody Conjugates And Uses ThereforUSPTOUS 11,554,181
PendingTumor Specific Antibody Conjugates And Uses ThereforUSPTOApplication PCTUS2019049336

Recent research by its founders

Untargeted Metabolomics Analysis Reveals Potential Metabolic Targets in Gemcitabine-Treated Pancreatic Cancer Cells20260 cites
Tumor-intrinsic interferon signaling drives pancreatic cancer resistance to tumor mucin1-targeted CAR T cell therapy20251 cites
199 | PEMBROLIZUMAB THERAPY INDUCES AN INFLAMMATORY RESPONSE IN LYMPHOMA PATIENTS BY RESHAPING MONOCYTES RESULTING IN HYPERPROGRESSIVE DISEASE20250 cites

VENTRIA BIOSCIENCESimilar federal contract value in Biotech · $305K in contracts
MIRECULE INCSimilar federal contract value in Biotech · $305K in contracts
AMYRIS, INC.Similar federal contract value in Biotech · $303K in contracts
Delphi Genomics, LLCSimilar federal contract value in Biotech · $300K in contracts
GENECURE LLCSimilar federal contract value in Biotech · $300K in contracts
Coordination Pharmaceuticals IncSimilar federal contract value in Biotech · $300K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.